Pediatric Gastroenterology, Hepatology & Nutrition

The Korean Society of Pediatric Gastroenterology, Hepatology and Nutrition (대한소아소화기영양학회)
권호 표지
DOI QR코드

DOI QR Code

Polymorphism in Macrophage Migration Inhibitory Factor -173GC in Pediatric Patients with Autoimmune Hepatitis

  • Alsayed, Mona Abdel Latif (Pediatric Gastroenterology and Hepatology Unit, Mansoura University Children's Hospital, Mansoura Faculty of Medicine, Mansoura University) ;
  • Elbeah, Shymaa Mohsen (Biochemistry Department, Mansoura Faculty of Medicine, Mansoura University) ;
  • El-Desoky, Manal M. (Biochemistry Department, Mansoura Faculty of Medicine, Mansoura University) ;
  • Elziny, Shereen Magdy (Pediatric Gastroenterology and Hepatology Unit, Mansoura University Children's Hospital, Mansoura Faculty of Medicine, Mansoura University) ;
  • Megahed, Ahmed (Pediatric Gastroenterology and Hepatology Unit, Mansoura University Children's Hospital, Mansoura Faculty of Medicine, Mansoura University)
  • Received : 2019.06.13
  • Accepted : 2019.09.13
  • Published : 2020.01.15
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: Autoimmune hepatitis (AIH) is a chronic disease that may lead to cirrhosis. The immunopathogenesis of AIH is not fully understood and it mainly involves T-cell mediated mechanism. Macrophage migration inhibitory factor (MIF) is a pro-inflammatory cytokine that promotes T cell response and its polymorphism may serve as a severity marker of AIH. No previous study has considered investigating MIF polymorphism in children with AIH. Methods: Forty-two children with definite diagnosis of AIH were enrolled along with 100 age and sex matched controls. All participants were tested for polymorphism at -173GC (rs755622) of MIF gene. All patients received the standard protocol of steroid plus azathioprine to achieve remission. Liver biopsy was performed at time of diagnosis for all patients and only 18 of them underwent a second biopsy after treatment. Results: No statistically significant differences in the frequency of the genotypes GG and GC or in allele distribution were found in both patient and control groups (p=0.590, 0.640 respectively). Initial alanine aminotransferase (ALT) levels at the time of presentation was significantly higher in the GC group than GG group (p=0.020). GC genotype significantly correlated with disease relapse (r=0.41, p=0.007). Regression of necroinflammation and the fibrosis score in the second liver biopsy was statistically significant in the GG group (p<0.0001, p=0.010 respectively). Conclusion: MIF -173GC polymorphism is associated with clinically significant markers of pediatric AIH, including increased initial serum ALT levels, may help predict necroinflammatory/fibrosis regression effectively, following immunosuppressive treatment.

Keywords

References

  1. Maggiore G, Veber F, Bernard O, Hadchouel M, Homberg JC, Alvarez F, et al. Autoimmune hepatitis associated with anti-actin antibodies in children and adolescents. J Pediatr Gastroenterol Nutr 1993;17:376-81. https://doi.org/10.1097/00005176-199311000-00007
  2. Mieli-Vergani G, Heller S, Jara P, Vergani D, Chang MH, Fujisawa T, et al. Autoimmune hepatitis. J Pediatr Gastroenterol Nutr 2009;49:158-64. https://doi.org/10.1097/MPG.0b013e3181a1c265
  3. Gregorio GV, Portmann B, Reid F, Donaldson PT, Doherty DG, McCartney M, et al. Autoimmune hepatitis in childhood: a 20-year experience. Hepatology 1997;25:541-7. https://doi.org/10.1002/hep.510250308
  4. Mieli-Vergani G, Vergani D. Autoimmune paediatric liver disease. World J Gastroenterol 2008;14:3360-7. https://doi.org/10.3748/wjg.14.3360
  5. Czaja AJ, Menon KV, Carpenter HA. Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: a retrospective analysis. Hepatology 2002;35:890-7. https://doi.org/10.1053/jhep.2002.32485
  6. Czaja AJ. Difficult treatment decisions in autoimmune hepatitis. World J Gastroenterol 2010;16:934-47. https://doi.org/10.3748/wjg.v16.i8.934
  7. de Boer YS, van Gerven NM, Zwiers A, Verwer BJ, van Hoek B, van Erpecum KJ, et al.. Genome-wide association study identifies variants associated with autoimmune hepatitis type 1. Gastroenterology 2014;147:443-52.e5. https://doi.org/10.1053/j.gastro.2014.04.022
  8. Czaja AJ, Manns MP. Advances in the diagnosis, pathogenesis, and management of autoimmune hepatitis. Gastroenterology 2010;139:58-72.e4. https://doi.org/10.1053/j.gastro.2010.04.053
  9. Vergani D, Mieli-Vergani G. Aetiopathogenesis of autoimmune hepatitis. World J Gastroenterol 2008;14:3306-12. https://doi.org/10.3748/wjg.14.3306
  10. Calandra T, Bernhagen J, Metz CN, Spiegel LA, Bacher M, Donnelly T, et al. MIF as a glucocorticoid-induced modulator of cytokine production. Nature 1995;377:68-71. https://doi.org/10.1038/377068a0
  11. Bucala R. MIF, MIF alleles, and prospects for therapeutic intervention in autoimmunity. J Clin Immunol 2013;33 Suppl 1:S72-8. https://doi.org/10.1007/s10875-012-9781-1
  12. Assis DN, Leng L, Du X, Zhang CK, Grieb G, Merk M, et al. The role of macrophage migration inhibitory factor in autoimmune liver disease. Hepatology 2014;59:580-91. https://doi.org/10.1002/hep.26664
  13. Assis DN, Takahashi H, Leng L, Zeniya M, Boyer JL, Bucala R. A macrophage migration inhibitory factor polymorphism is associated with autoimmune hepatitis severity in US and Japanese patients. Dig Dis Sci 2016;61:3506-12. https://doi.org/10.1007/s10620-016-4322-z
  14. Hennes EM, Zeniya M, Czaja AJ, Pares A, Dalekos GN, Krawitt EL, et al.; International Autoimmune Hepatitis Group. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 2008;48:169-76. https://doi.org/10.1002/hep.22322
  15. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696-9. https://doi.org/10.1016/0168-8278(95)80226-6
  16. Roberts S, Leng L, Soroka CJ, Boyer JL, Bucala R, Assis DN. Macrophage migration inhibitory factor (MIF) modulates T-cell proliferation and hepatic inflammation in a model of autoimmune liver disease. J Hepatol 2017;66:S363-4.
  17. Sreih A, Ezzeddine R, Leng L, LaChance A, Yu G, Mizue Y, et al. Dual effect of the macrophage migration inhibitory factor gene on the development and severity of human systemic lupus erythematosus. Arthritis Rheum 2011;63:3942-51. https://doi.org/10.1002/art.30624
  18. Foote A, Briganti EM, Kipen Y, Santos L, Leech M, Morand EF. Macrophage migration inhibitory factor in systemic lupus erythematosus. J Rheumatol 2004;31:268-73.
  19. Llamas-Covarrubias MA, Valle Y, Bucala R, Navarro-Hernandez RE, Palafox-Sanchez CA, Padilla-Gutierrez JR, et al. Macrophage migration inhibitory factor (MIF): genetic evidence for participation in early onset and early stage rheumatoid arthritis. Cytokine 2013;61:759-65. https://doi.org/10.1016/j.cyto.2012.12.032
  20. Zhang H, Ma L, Dong LQ, Shu C, Xu JL. Association of the macrophage migration inhibitory factor gene--173G/C polymorphism with inflammatory bowel disease: a meta-analysis of 4296 subjects. Gene 2013;526:228-31. https://doi.org/10.1016/j.gene.2013.05.012
  21. Berdeli A, Mir S, Ozkayin N, Serdaroglu E, Tabel Y, Cura A. Association of macrophage migration inhibitory factor -173C allele polymorphism with steroid resistance in children with nephrotic syndrome. Pediatr Nephrol 2005;20:1566-71. https://doi.org/10.1007/s00467-005-1930-9
  22. Arikan C, Berdeli A, Ozgenc F, Tumgor G, Yagci RV, Aydogdu S. Positive association of macrophage migration inhibitory factor gene-173G/C polymorphism with biliary atresia. J Pediatr Gastroenterol Nutr 2006;42:77-82. https://doi.org/10.1097/01.mpg.0000192247.55583.fa
  23. Sadek KH, Ezzat S, Abdel-Aziz SA, Alaraby H, Mosbeh A, Abdel-Rahman MH. Macrophage migration inhibitory factor (MIF) gene promotor polymorphism is associated with increased fibrosis in biliary atresia patients, but not with disease susceptibility. Ann Hum Genet 2017;81:177-83. https://doi.org/10.1111/ahg.12199
  24. Akyildiz M, Gunsar F, Nart D, Sahin O, Yilmaz F, Akay S, et al. Macrophage migration inhibitory factor expression and MIF gene -173 G/C polymorphism in nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 2010;22:192-8. https://doi.org/10.1097/MEG.0b013e328331a596
  25. Moudi B, Heidari Z, Mahmoudzadeh-Sagheb H, Hashemi M. Gene polymorphisms of macrophage migration inhibitory factor affect susceptibility to chronic hepatitis B virus infection in an Iranian cohort. Microbiol Immunol 2016;60:390-6. https://doi.org/10.1111/1348-0421.12382
  26. Zhang HY, Nanji AA, Luk JM, Huang XR, Lo CM, Chen YX, et al. Macrophage migration inhibitory factor expression correlates with inflammatory changes in human chronic hepatitis B infection. Liver Int 2005;25:571-9. https://doi.org/10.1111/j.1478-3231.2005.01047.x
  27. Zhang K, Pan X, Shu X, Cao H, Chen L, Zou Y, et al. Relationship between MIF-173 G/C polymorphism and susceptibility to chronic hepatitis B and HBV-induced liver cirrhosis. Cell Immunol 2013;282:113-6. https://doi.org/10.1016/j.cellimm.2013.04.013
  28. Bahgat DMR, Said S, Gheith RE. Non-significant influence of macrophage migration inhibitory factor (MIF) promoter gene polymorphisms on the risk or activity of Egyptian Behcet's disease patients: potential role of MIF+254T/C in posterior uveitis. Egypt Rheumatol 2017;39:115-20. https://doi.org/10.1016/j.ejr.2017.01.003
  29. El-Edel RH, El-Din RIN, El-Zayat RS, El-Bagoury HAM. Association of macrophage migration inhibitory factor -173G/C polymorphism with dilated cardiomyopathy in children. Menoufia Med J 2018;31:306-10.
  30. Radstake TR, Sweep FC, Welsing P, Franke B, Vermeulen SH, Geurts-Moespot A, et al. Correlation of rheumatoid arthritis severity with the genetic functional variants and circulating levels of macrophage migration inhibitory factor. Arthritis Rheum 2005;52:3020-9. https://doi.org/10.1002/art.21285

Cited by

  1. Pathogenesis of autoimmune hepatitis vol.13, pp.8, 2020, https://doi.org/10.4254/wjh.v13.i8.879